We are international
Donate
special ASH update TEXT SIZE   

ASH 2006 - Webcasts
previous     next      view all

Novel Agents - Newly-Diagnosed Myeloma
12.17.06   Phase I/II Study of Revlimid + Melphalan/Prednisone (R-MP) for Newly Diagnosed Myeloma
Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy

12.17.06   Relationship Between Quality of Response to Velcade and Clinical Benefit
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY

12.17.06   Revlimid-Induced Myelosuppression is Potentially Associated with Renal Dysfunction in Treatment-Naïve MM Patients Receiving BiRD
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY

12.17.06   The Use of Lenalidomide +/- Dexamethasone in Patients with AL Amyloidosis
Angela Dispenzieri, MD
Mayo Clinic
Rochester, MN

12.17.06   The Use of Velcade + Melphalan/Prednisone in Elderly Non-Transplant Patients
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain

12.17.06   The Use of Velcade as First-Line Therapy in High-Risk Myeloma
Angela Dispenzieri, MD
Mayo Clinic
Rochester, MN

12.17.06   Use of Revlimid With or Without Steroids in Relapsed/Refractory Myeloma Patients with Elevated Baseline Serum Creatinine
Donna E. Reece, MD
Princess Margaret Hospital
Toronto, Canada

12.17.06   Velcade and Doxil as Induction Therapy for Newly Diagnosed Myeloma
Robert Z. Orlowski, MD
Lineberger Cancer Center
University of North Carolina
Chapel Hill, NC

Novel Agents - Relapsed/Refractory Myeloma
12.17.06   A Phase I/II Study of Revlimid, Adriamycin, and Dexamethasone (RAD) in Patients with Relapsed/Refractory Myeloma
Stefan Knop, MD
Universitätsklinikums Würzburg (University Clinic of Wuerzburg)
Würzburg, Germany

12.17.06   A Phase II Study of Velcade, Doxil, and Thalidomide (VDT) in Relapsed/Refractory Myeloma
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY

previous     next      view all